Einzeltreffer — DigiBib

Infectious laryngotracheitis (ILT) is a respiratory disease that causes significant economic losses to the poultry industry. Control of the disease is achieved by vaccination and implementation of biosecurity measures. The use of bivalent and trivalent recombinant herpesvirus of turkey (rHVT) vaccines expressing infectious laryngotracheitis virus (ILTV) genes has increased worldwide. In the United States, vaccination programs of long-lived birds (broiler breeders and commercial layers) against ILT include immunizations with either HVT recombinant vector vaccines, in ovo or at hatch, or live attenuated vaccines administered via drinking water (chicken embryo origin [CEO]) or eye drop (tissue culture origin [TCO]). The efficacy of bivalent rHVT-LT at hatch followed by drinking water or eye-drop CEO vaccination has been shown to provide more robust protection than rHVT-LT alone. The objective of this study was to evaluate the protection efficacy of a commercial trivalent rHVT-ND-LT when administered at 1 day of age followed by TCO vaccination via eye drop at 10 wk of age. Groups vaccinated with only rHVT-ND-LT or TCO, the combination of rHVT-ND-LT + TCO, and one nonvaccinated group of chickens were challenged with a virulent ILTV strain at 15 wk of age. After challenge, mortalities were prevented only in the group of chickens vaccinated with the rHVT-ND-LT + TCO. Clinical signs of the disease and challenge virus replication in the trachea were significantly reduced for both the rHVT-ND-LT + TCO- and TCO-vaccinated groups of chickens. To assess challenge virus transmission, contact-naive chickens were introduced to all vaccinated groups immediately after challenge. At 8 days postintroduction, infection of contact-naive chickens was evidenced in those introduced to the rHVT-ND-LT and TCO group but prevented in the rHVT-ND-LT + TCO group. Overall, these results indicated that compared to rHVT-ND-LT or TCO when administered alone, the rHVT-ND-LT + TCO vaccination strategy improved protection against disease and reduced shedding of the challenge virus.

Titel:	Protection Efficacy of Recombinant HVT-ND-LT and the Live Attenuated Tissue Culture Origin Vaccines Against Infectious Laryngotracheitis Virus When Administered Individually or in Combination.
Autor/in / Beteiligte Person:	Becerra, R ; Maekawa, D ; García, M
Zeitschrift:	Avian diseases, Jg. 67 (2023-06-01), Heft 2, S. 145-152
Veröffentlichung:	Kennett Square Pa : American Association Of Avian Pathologists ; <i>Original Publication</i>: Ithaca, N. Y., American Association of Avian Pathologists., 2023
Medientyp:	academicJournal
ISSN:	1938-4351 (electronic)
DOI:	10.1637/aviandiseases-D-23-00010
Schlagwort:	Chick Embryo Animals Chickens Vaccines, Attenuated Vaccination veterinary Turkeys Vaccines, Synthetic Herpesviridae Infections prevention & control Herpesviridae Infections veterinary Drinking Water Viral Vaccines Poultry Diseases prevention & control Herpesvirus 1, Gallid
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Avian Dis] 2023 Jun; Vol. 67 (2), pp. 145-152. MeSH Terms: Herpesviridae Infections* / prevention & control ; Herpesviridae Infections* / veterinary ; Drinking Water* ; Viral Vaccines* ; Poultry Diseases* / prevention & control ; Herpesvirus 1, Gallid* ; Chick Embryo ; Animals ; Chickens ; Vaccines, Attenuated ; Vaccination / veterinary ; Turkeys ; Vaccines, Synthetic References: Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ, Minson AC, Pellett PE, Roizman B, Studdert MJ, Thiry E. The order Herpesvirales. Arch. Virol . 154:171–177; 2009. ; García M, Spatz S. Infectious laryngotracheitis. In: Swayne DE, Boulianne M, Logue CM, McDougald LR, Nair V, Suarez DL, editors. Diseases of poultry . 14th ed. Hoboken (NJ): Wiley-Blackwell. p. 189–209; 2020. ; Guy JS, Barnes HJ, Morgan LM. Virulence of infectious laryngotracheitis viruses: comparison of modified-live vaccine viruses and North Carolina field isolates. Avian Dis . 34:106–113; 1990. ; Guy JS, Barnes HJ, Smith L. Increased virulence of modified-live infectious laryngotracheitis vaccine virus following bird-to-bird passage. Avian Dis . 35:348–355; 1991. ; Rodríguez-Avila A, Oldoni I, Riblet S, García M. Replication and transmission of live attenuated infectious laryngotracheitis virus (ILTV) vaccines. Avian Dis . 51:905–911; 2007. ; Chacón JL, Ferreira AJP. Differentiation of field isolates and vaccine strains of infectious laryngotracheitis virus by DNA sequencing. Vaccine 27:6731–6738; 2009. ; Neff C, Sudler C, Hoop RK. Characterization of western European field isolates and vaccine strains of avian infectious laryngotracheitis virus by restriction fragment length polymorphism and sequence analysis. Avian Dis . 52:278–283; 2008. ; Oldoni I, Rodríguez-Avila A, Riblet S, García M. Characterization of infectious laryngotracheitis virus (ILTV) isolates from commercial poultry by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Avian Dis . 52:59–63; 2008. ; Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet J-C, Mickle TR. Development and use of fowlpox vectored vaccines for avian influenza. Ann. N. Y. Acad. Sci . 1081:193–201; 2006. ; Esaki M, Noland L, Eddins T, Godoy A, Saeki S, Saitoh S, Yasuda A, Dorsey KM. Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens. Avian Dis . 57:192–198; 2013. ; García M, Zavala G. Commercial vaccines and vaccination strategies against infectious laryngotracheitis: what we have learned and knowledge gaps that remain. Avian Dis . 63:325–334; 2019. ; Hein R, Koopman R, García M, Armour N, Dunn JR, Barbosa T, Martinez A. Review of poultry recombinant vector vaccines. Avian Dis . 65:438–452; 2021. ; Gergen L, Cook S, Ledesma B, Cress W, Higuchi D, Counts D, Cruz-Coy J, Crouch C, Davis P, Tarpey I, et al. A double recombinant herpes virus of turkeys for the protection of chickens against Newcastle, infectious laryngotracheitis and Marek's diseases. Avian Pathol . 48:45–56; 2018. ; Maekawa D, Riblet SM, Newman L, Koopman R, Barbosa T, García M. Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination. Avian Pathol . 48:573–581; 2019. ; Maekawa D, Riblet SM, Whang P, Alvarado I, García M. A cell line adapted infectious laryngotracheitis virus strain (BΔORFC) for in ovo and hatchery spray vaccination alone or in combination with a recombinant HVT-LT vaccine. Avian Dis . 65:500–507; 2021. ; Oldoni I, Rodríguez-Avila A, Riblet SM, Zavala G, García M. Pathogenicity and growth characteristics of selected infectious laryngotracheitis virus strains from the United States. Avian Pathol . 38:47–53; 2009. ; Reed L, Muench H. A simple method of estimating fifty percent end-points. Am J Trop Med Hyg . 27:493–497; 1938. ; Maekawa D, Whang P, Riblet SM, Hurley DJ, Guy JS, García M. Assessing the infiltration of immune cells in the upper trachea mucosa after infectious laryngotracheitis virus (ILTV) vaccination and challenge. Avian Pathol . 50:540–556; 2021. ; Islam AF, Harrison B, Cheetham BF, Mahony TJ, Young PL, Walkden-Brown SW. Differential amplification and quantitation of Marek's disease viruses using real-time polymerase chain reaction. J Virol Methods 119:103–113; 2004. ; Vagnozzi A, Zavala G, Riblet SM, Mundt A, García M. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens. Avian Pathol . 41:21–31; 2012. ; Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408; 2001. ; GraphPad by Dotmatics. GraphPad Prism , version 8. La Jolla (CA): GraphPad Software, Inc. http://www.graphpad.com/scientific-software/prism/; 2018. ; Garcia M, Spatz SJ, Cheng Y, Riblet SM, Volkening JD, Schneiders GH. Attenuation and protection efficacy of ORF C gene-deleted recombinant of infectious laryngotracheitis virus. J Gen Virol . 97:2352–2362; 2016. ; Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, García M. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines. Avian Dis . 54:1251–1259; 2010. ; Palomino-Tapia VA, Zavala G, Cheng S, García M. Long-term protection against a virulent field isolate of infectious laryngotracheitis virus induced by inactivated, recombinant, and modified live virus vaccines in commercial layers. Avian Pathol . 48:209–220; 2019. ; Barboza-Solis C, Najimudeen SM, Perez-Contreras A, Ali A, Joseph T, King R, Ravi M, Peters D, Fonseca K, Gagnon CA. Evaluation of recombinant herpesvirus of turkey laryngotracheitis (rHVT-LT) vaccine against genotype VI Canadian wild-type infectious laryngotracheitis virus (ILTV) infection. Vaccines 9:1425; 2021. doi:10.3390/vaccines9121425. ; Maekawa D, Riblet SM, Whang P, Hurley DJ, Garcia M. Activation of cytotoxic lymphocytes and presence of regulatory t cells in the trachea of non-vaccinated and vaccinated chickens as a recall to an infectious laryngotracheitis virus (ILTV) challenge. Vaccines 9:865; 2021. doi:10.3390/vaccines9080865. ; Maekawa D, Beltrán G, Riblet SM, García M. Protection efficacy of a recombinant herpesvirus of turkey vaccine against infectious laryngotracheitis virus administered in ovo to broilers at three standardized doses. Avian Dis . 63:351–358; 2019. Contributed Indexing: Keywords: infectious laryngotracheitis; tissue culture origin; trivalent rHVT-ND-LT; vaccination ; Local Abstract: [Publisher, Spanish; Castilian] Eficacia protectora de las vacunas recombinantes HVT-ND-LT y las vacunas con virus vivo atenuado con origen en cultivo de tejidos contra el virus de la laringotraqueítis infecciosa cuando son administradas individualmente o en combinación. La laringotraqueítis infecciosa (ILT) es una enfermedad respiratoria que causa importantes pérdidas económicas a la industria avícola. El control de la enfermedad se logra mediante la vacunación y la implementación de medidas de bioseguridad. El uso de vacunas con el herpesvirus de pavo recombinante (rHVT) bivalentes y trivalentes que expresan genes del virus de la laringotraqueítis infecciosa (ILTV) ha aumentado en todo el mundo. En los Estados Unidos, los programas de vacunación de aves de larga vida (reproductoras pesadas y aves de postura comerciales) contra la laringotraqueítis incluyen inmunizaciones con vacunas con vector HVT recombinante, ya sea in ovo o al día de edad en la planta incubadora, o la aplicación de vacunas vivas atenuadas administradas a través del agua de bebida (origen en embrión de pollo [CEO]) o por gota ocular (origen en cultivo de tejidos [TCO]). Se ha demostrado que la eficacia de la vacuna rHVT-LT bivalente aplicada al día de edad en incubadora, seguida de la inmunización con la vacuna CEO en el agua de bebida o por gota ocular, proporciona una protección más sólida que la aplicación únicamente de la vacuna rHVT-LT. El objetivo de este estudio fue evaluar la eficacia protectora de una vacuna recombinante rHVT-ND-LT trivalente comercial cuando se administró al día de vida seguido de la vacunación con la vacuna TCO mediante gota ocular a las 10 semanas de edad. Los grupos vacunados únicamente con la vacuna rHVT-ND-LT, con TCO, la combinación con rHVT-ND-LT + TCO y un grupo de pollos no vacunados fueron desafiados con una cepa virulenta del virus de la laringotraqueítis a las 15 semanas de edad. Después del desafío, se previno la mortalidad únicamente en el grupo de pollos vacunados con la combinación rHVT-ND-LT + TCO. Los signos clínicos de la enfermedad y la replicación del virus de desafío en la tráquea se redujeron significativamente en los grupos de pollos vacunados con la combinación rHVT-ND-LT + TCO y con la vacuna TCO. Para evaluar la transmisión del virus de desafío, pollos sin contacto previo al virus se introdujeron en todos los grupos vacunados inmediatamente después del desafío. A los 8 días posteriores a la introducción, se evidenció la infección de los pollos sin contacto previo que se introdujeron en los grupos que recibieron únicamente la vacuna rHVT-ND-LT o la vacuna TCO, pero se previno en el grupo con la combinación rHVT-ND-LT + TCO. En general, estos resultados indicaron que, en comparación con las vacunas rHVT-ND-LT o TCO cuando se administran solas, la estrategia de vacunación rHVT-ND-LT + TCO mejoró la protección contra la enfermedad y redujo la diseminación del virus de desafío. Substance Nomenclature: 0 (Vaccines, Attenuated) ; 0 (Drinking Water) ; 0 (Viral Vaccines) ; 0 (Vaccines, Synthetic) Entry Date(s): Date Created: 20230809 Date Completed: 20230811 Latest Revision: 20230811 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Protection Efficacy of Recombinant HVT-ND-LT and the Live Attenuated Tissue Culture Origin Vaccines Against Infectious Laryngotracheitis Virus When Administered Individually or in Combination.